Search in:

Advanced search

Vascular Health and Risk Management Volume 11, 2015 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Harold E Bays1 Louisville Metabolic & Atherosclerosis Research Center (L-MARC), Louisville, KY, USA

Eliot A Brinton2 Utah Foundation for Biomedical Research, Salt Lake City, UT, USA

Joseph Triscari3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Erluo Chen3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Darbie Maccubbin3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Alexandra A MacLean3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Kendra L Gibson3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Rae Ann Ruck3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Amy O Johnson-Levonas3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Edward A O’Neill3 Merck & Co, Inc., Whitehouse Station, NJ, USA

Yale B Mitchel3 Merck & Co, Inc., Whitehouse Station, NJ, USACorrespondence[email protected]

show all

Pages 165-172 | Published online: 24 Feb 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

HaffnerSMDyslipidemia management in adults with diabetesDiabetes Care200427Suppl 1S68S7114693930
PubMedGoogle Scholar
GottoAMJrHigh-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery diseaseAm Heart J2002144S33S4212486414
PubMed Web of Science ®Google Scholar
ManzatoEZambonALapollaALipoprotein abnormalities in well-treated type II diabetic patientsDiabetes Care1993164694758432219
PubMed Web of Science ®Google Scholar
MoraSOtvosJDRosensonRSPradhanABuringJERidkerPMLipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in womenDiabetes2010591153116020185808
PubMed Web of Science ®Google Scholar
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation20021063143342112485966
PubMed Web of Science ®Google Scholar
BaysHEBallantyneCWhat’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?Curr Opin Lipidol20092046747619779335
PubMed Web of Science ®Google Scholar
GuytonJRBlazingMAHagarJExtended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study GroupArch Intern Med20001601177118410789612
PubMedGoogle Scholar
McKenneyJMMcCormickLSSchaeferEJBlackDMWatkinsMLEffect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemiaAm J Cardiol20018827027411472706
PubMed Web of Science ®Google Scholar
MorganJMCapuzziDMBakshRIEffects of extended-release niacin on lipoprotein subclass distributionAm J Cardiol2003911432143612804729
PubMed Web of Science ®Google Scholar
BirjmohunRSHuttenBAKasteleinJJStroesESIncreasing HDL cholesterol with extended-release nicotinic acid: from promise to practiceNeth J Med20046222923415554597
PubMed Web of Science ®Google Scholar
IllingworthDRSteinEAMitchelYBComparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trialArch Intern Med1994154158615958031206
PubMed Web of Science ®Google Scholar
Kamal-BahlSJBurkeTAWatsonDJWentworthCEDosage, titration, and gaps in treatment with extended release niacin in clinical practiceCurr Med Res Opin2008241817182118485268
PubMed Web of Science ®Google Scholar
KnoppRHGinsbergJAlbersJJContrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacinMetabolism1985346426503925290
PubMed Web of Science ®Google Scholar
MillsEProuskyJRaskinGThe safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]BMC Clin Pharmacol20033414614780
PubMedGoogle Scholar
PaoliniJFMitchelYBReyesREffects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaAm J Cardiol200810162563018308010
PubMed Web of Science ®Google Scholar
SturinoCFO’NeillGLachanceNDiscovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b] indol-3-Yl]-acetic acid (MK-0524)J Med Chem20075079480617300164
PubMed Web of Science ®Google Scholar
BergeKGCannerPLCoronary drug project: experience with niacin. Coronary Drug Project Research GroupEur J Clin Pharmacol199140Suppl 1S49S512044644
PubMedGoogle Scholar
BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med1990323128912982215615
PubMed Web of Science ®Google Scholar
BodenWEProbstfieldJLAndersonTNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med20113652255226722085343
PubMed Web of Science ®Google Scholar
HPS2-THRIVE Collaborative GroupHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J2013341279129123444397
PubMed Web of Science ®Google Scholar
LandrayMJHaynesRHopewellJCEffects of extended-release niacin with laropiprant in high-risk patientsN Engl J Med201437120321225014686
PubMed Web of Science ®Google Scholar
BeckmanJACreagerMALibbyPDiabetes and atherosclerosis: epidemiology, pathophysiology, and managementJAMA20022872570258112020339
PubMed Web of Science ®Google Scholar
MacLeanAMcKenneyJMScottREfficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitusBr J Cardiol2011183745
Google Scholar
JellingerPSSmithDAMehtaAEAmerican association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosisEndocr Pract201218Suppl 117822522068
PubMedGoogle Scholar
GuytonJRSleeAEAndersonTRelationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes)J Am Coll Cardiol2013621580158423916935
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date